# Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Carbapenem-resistant Enterbacterales (CRE) Infections

> **NIH NIH N01** · DYNPORT VACCINE COMPANY, LLC · 2024 · $844,653

## Abstract

The Early Phase Clinical Trial Units provide a vehicle for investigation of new agents in the treatment and prevention of infectious diseases and can carry out all aspects of interventional clinical trial implementation.

## Key facts

- **NIH application ID:** 11041972
- **Project number:** 272201500005I-P00004-759302200057-1
- **Recipient organization:** DYNPORT VACCINE COMPANY, LLC
- **Principal Investigator:** GRAIG SHOCKEY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $844,653
- **Award type:** —
- **Project period:** 2021-12-14 → 2024-05-06

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11041972

## Citation

> US National Institutes of Health, RePORTER application 11041972, Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Carbapenem-resistant Enterbacterales (CRE) Infections (272201500005I-P00004-759302200057-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11041972. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*